Dupixent EOE denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent eoe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Step Therapy Before Approving Dupixent for EoE

Step therapy (also called "fail-first") for Dupixent in eosinophilic esophagitis means UHC requires documentation that the patient has tried and had an inadequate response to one or more less-expensive therapies before approving the biologic. For EoE, required steps typically involve dietary modification, proton-pump inhibitor therapy, and/or topical corticosteroid therapy. A step-therapy denial does not mean Dupixent is excluded — it means the clinical record submitted did not clearly demonstrate completion of the required prior steps, or the forms did not address them.

## Why This Denial Is Appealable

Step therapy protocols must be clinically appropriate and cannot require a patient to try a therapy that is contraindicated, unavailable, or that they have already tried and failed. If the patient has genuinely completed the required prior steps and the documentation supports that, the denial is a documentation problem, not a coverage problem. If the step-therapy requirement forces the patient to retry a treatment they have already failed — or one that poses a clinical risk — that is independently appealable.

## Federal Appeal Framework

• Step therapy exception: Most UHC plans have a formal step-therapy exception process. File this first. The prescriber attests that required steps have been completed or are clinically inappropriate.
• Internal appeal: File within the deadline on the denial notice. Many states now have step-therapy override laws; check whether your state's law applies to this plan.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeal, request independent external review. File within approximately four months of the final internal denial (confirm exact date on the denial notice). External reviewers assess whether the step-therapy requirement is consistent with generally accepted standards of care for EoE.
• Expedited track: Available if delay poses a serious health risk.

## Documentation to Gather

1. Prior therapy records: For each required step therapy, provide: the treatment name, start date, end date or current status, reason for discontinuation (inadequate response, adverse effect, clinical contraindication), and the prescriber's assessment at the time. 2. Confirmed EoE diagnosis: Biopsy pathology, gastroenterologist's diagnostic note, symptom history. 3. Current clinical status: Chart notes showing ongoing or worsening disease despite prior therapies. 4. Prescriber step-therapy exception letter: A letter that identifies each step UHC requires, confirms completion or explains why each could not be completed, and documents the patient's current clinical need for dupilumab specifically.

## Criteria-Mapping Structure

Obtain UHC's step-therapy criteria for dupilumab-EoE from the Provider Portal. List each required step verbatim. For each step, cite the clinical record entries that document attempt, duration, and outcome — including dates. If a step was skipped because it was clinically inappropriate for this patient, document that with a prescriber attestation. A clear, step-by-step match between the protocol and the chart is the fastest path to reversal.